Unity Biotechnology (NASDAQ:UBX) Downgraded to "Hold" at Zacks Investment Research

Last updated on Tuesday, January 26, 2021 | 2021 MarketBeat

Unity Biotechnology (NASDAQ:UBX) was downgraded by Zacks Investment Research from a "buy" rating to a "hold" rating in a note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, "UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. "

UBX stock traded down $0.43 during midday trading on Tuesday, hitting $6.30. The stock had a trading volume of 12,133 shares, compared to its average volume of 955,734. The firm has a market cap of $333.35 million, a PE ratio of -3.37 and a beta of 0.36. Unity Biotechnology has a 12-month low of $2.72 and a 12-month high of $15.44. The company's 50-day moving average price is $6.01 and its 200 day moving average price is $5.58.

Unity Biotechnology (NASDAQ:UBX) last released its earnings results on Wednesday, November 4th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by ($0.07). On average, equities research analysts anticipate that Unity Biotechnology will post -1.66 EPS for the current fiscal year.

In other Unity Biotechnology news, President Nathaniel E. David sold 1,700,000 shares of Unity Biotechnology stock in a transaction on Wednesday, December 16th. The shares were sold at an average price of $5.24, for a total value of $8,908,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 37.30% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Advisor Group Holdings Inc. lifted its holdings in shares of Unity Biotechnology by 4,646.0% during the 2nd quarter. Advisor Group Holdings Inc. now owns 4,746 shares of the company's stock valued at $41,000 after acquiring an additional 4,646 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Unity Biotechnology by 554.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 7,926 shares of the company's stock valued at $27,000 after acquiring an additional 6,715 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Unity Biotechnology during the 3rd quarter valued at $36,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Unity Biotechnology during the 3rd quarter valued at $44,000. Finally, Arbor Wealth Management LLC acquired a new position in shares of Unity Biotechnology during the 3rd quarter valued at $72,000. Institutional investors own 37.21% of the company's stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases.

Featured Story: Cash Flow

Get a free copy of the Zacks research report on Unity Biotechnology (UBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Unity Biotechnology (NASDAQ:UBX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Penny Stocks That Don’t Care About Robinhood

By the time you read this Vladimir Tenev, the CEO of the trading app Robinhood, will be testifying in front of Congress. The company’s role in the GameStop (NYSE:GME) short squeeze will be called into question.

However, the real issue at stake is the right of traders to buy and sell the equities of their choice. In the case of Robinhood, some traders are buying a lot of penny stocks. While definitions vary, penny stocks are generally considered stocks that are trading for less than $10 per share. These stocks are largely ignored by the investment community.

One reason is that many of these stocks are cheap for a reason. For example, the company may have a business model that is out of date. In other cases, they operate in a very small, niche market that doesn’t drive a lot of revenue.

And most of these stocks are ignored by the investment community. They simply aren’t considered significant enough to spend time debating.

But some penny stocks do have the attention of Wall Street. And they’re being largely ignored by the day trading community. The focus of this special presentation is to direct you to penny stocks that have a story that the “smart money” thinks will eventually be trading at much higher prices.

And that’s why you should be looking at them now.

View the "7 Penny Stocks That Don’t Care About Robinhood".

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.